Involvement of Tis11b, an AU-rich binding protein, in induction of apoptosis by rituximab in B cell chronic lymphocytic leukemia cells

被引：22

作者：

Baou, M. ^{[5
]}

Jewell, A. ^{[1
,2
]}

Muthurania, A. ^{[5
]}

Wickremasinghe, R. G. ^{[3
]}

Yong, K. L. ^{[3
]}

Carr, R. ^{[4
]}

Marsh, P.

Murphy, J. J. ^{[5
]}

机构：

[1] Kingston Univ, Fac Hlth & Social Care Sci, London, England

[2] Gen Hosp St Georg, Sch Med, London, England

[3] UCL, Sch Med, Dept Haematol, London W1N 8AA, England

[4] Kings Coll London, Guys Hosp, Dept Haematol, London WC2R 2LS, England

[5] Kings Coll London, Div Immunol Infect & Inflammatory Dis, London WC2R 2LS, England

来源：

LEUKEMIA | 2009年 / 23卷 / 05期

关键词：

TRISTETRAPROLIN; KINASE;

D O I：

10.1038/leu.2008.340

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：986 / 989

页数：4

共 8 条

[1] Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways [J].

Brook, M ;

Tchen, CR ;

Santalucia, T ;

McIlrath, J ;

Arthur, JSC ;

Saklatvala, J ;

Clark, AR .

MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (06) :2408-2418

[2] Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].

Byrd, JC ;

Peterson, BL ;

Morrison, VA ;

Park, K ;

Jacobson, R ;

Hoke, E ;

Vardiman, JW ;

Rai, K ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2003, 101 (01) :6-14

[3] MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding [J].

Chrestensen, CA ;

Schroeder, MJ ;

Shabanowitz, J ;

Hunt, DF ;

Pelo, JW ;

Worthington, MT ;

Sturgill, TW .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (11) :10176-10184

[4] Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines [J].

Cittera, E ;

Onofri, C ;

D'Apolito, M ;

Cartron, G ;

Cazzaniga, G ;

Zelante, L ;

Paolucci, P ;

Biondi, A ;

Introna, M ;

Golay, J .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (03) :273-286

[5] Similar but distinct effects of the tristetraprolin/TIS11 immediate-early proteins on cell survival [J].

Johnson, BA ;

Geha, M ;

Blackwell, TK .

ONCOGENE, 2000, 19 (13) :1657-1664

[6] Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines [J].

Lee, SK ;

Kim, SB ;

Kim, JS ;

Moon, CH ;

Han, MS ;

Lee, BJ ;

Chung, DK ;

Min, YJ ;

Park, JH ;

Choi, DH ;

Cho, HR ;

Park, SK ;

Park, JW .

INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (01) :32-40

[7] The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism [J].

Pedersen, IM ;

Buhl, AM ;

Klausen, P ;

Geisler, CH ;

Jurlander, J .

BLOOD, 2002, 99 (04) :1314-1319

[8] Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia [J].

Tsimberidou, Apostolia M. ;

Wierda, William G. ;

Plunkett, William ;

Kurzrock, Razelle ;

O'Brien, Susan ;

Wen, Sijin ;

Ferrajoli, Alessandra ;

Ravandi-Kashani, Farhad ;

Garcia-Manero, Guillermo ;

Estrov, Zeev ;

Kipps, Thomas J. ;

Brown, Jennifer R. ;

Fiorentino, Albert ;

Lerner, Susan ;

Kantarjian, Hagop M. ;

Keating, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :196-203

← 1 →